Advertisement

Neoadjuvant Trastuzumab and Docetaxel in Patients With Breast Cancer: Preliminary Results

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Trastuzumab/chemotherapy combinations have already shown superior results in metastatic breast cancer patients. The purpose of this study is to determine the clinical efficacy of neoadjuvant trastuzumab and docetaxel in women with locally advanced breast cancer, with or without metastatic disease. Treatment-naive women with HER2-overexpressing locally advanced breast cancer, with or without metastatic disease, were included. Patients received trastuzumab 4 mg/kg loading dose intravenously then 2 mg/kg weekly. On day 22, docetaxel 100 mg/m2 every 3 weeks for 4 cycles was added to weekly trastuzumab. Patients then underwent surgery and subsequent 4 cycles of AC (doxorubicin/cyclophosphamide; 60/600 mg/m2) without trastuzumab. Weekly trastuzumab was resumed 1 month after completion of AC and continued for a year. Preliminary results from the first 22 patients with median follow-up of 15.5 months (range, 2-38 months) are reported. Of these, 9 patients (40.9%) had inflammatory breast cancer, and 6 patients (27.3%) had stage IV breast cancer. Seventeen of 22 patients (77.3%) had objective clinical response, with a clinical complete response in 9 patients (40.9%). Two patients (9.1%) had decline in cardiac function and 7 patients (31.8%) experienced neutropenia, with 2 deaths (9.1%) from neutropenic sepsis. Eight patients (36.4%) have relapsed, 3 with local skin recurrence (13.6%) and 5 with distant recurrence, of whom 1 had liver metastasis (4.5%) and 4 had brain metastasis (18.2%). Combined neoadjuvant trastuzumab and docetaxel induced high clinical response rates for HER2- overexpressing breast cancer, in particular for inflammatory breast cancer. A high rate of brain metastasis was noted, particularly in patients with baseline metastatic disease.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Slamon DJ
        • Clark GM
        • Wong SG
        • et al.
        Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
        Science. 1987; 235: 177-182
        • Schlessinger J
        Cell signaling by receptor tyrosine kinases.
        Cell. 2000; 103: 211-225
        • Yarden Y
        • Sliwkowski MX
        Untangling the ErbB signalling network.
        Nat Rev Mol Cell Biol. 2001; 2: 127-137
        • Cho HS
        • Mason K
        • Ramyar KX
        • et al.
        Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.
        Nature. 2003; 421: 756-760
        • Pietras RJ
        • Pegram MD
        • Finn RS
        • et al.
        Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
        Oncogene. 1998; 17: 2235-2249
        • Cobleigh MA
        • Vogel CL
        • Tripathy D
        • et al.
        Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
        J Clin Oncol. 1999; 17: 2639-2648
        • Slamon DJ
        • Leyland-Jones B
        • Shak S
        • et al.
        Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
        N Engl J Med. 2001; 344: 783-792
        • Pegram M
        • Hsu S
        • Lewis G
        • et al.
        Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
        Oncogene. 1999; 18: 2241-2251
        • Konecny G
        • Fritz M
        • Untch M
        • et al.
        Her-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer.
        Breast Cancer Res Treat. 2001; 69: 53-63
        • Seidman A
        • Hudis C
        • Pierri MK
        • et al.
        Cardiac dysfunction in the trastuzumab clinical trials experience.
        J Clin Oncol. 2002; 20: 1215-1221
        • Nabholtz J-M
        • Reese DM
        • Lindsay M-A
        • et al.
        Docetaxel in the treatment of breast cancer: an update on recent studies.
        Semin Oncol. 2002; 29: 28-34
        • Witters LM
        • Santala SM
        • Engle L
        • et al.
        Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells.
        Am J Clin Oncol. 2003; 26: 50-54
        • Uber K
        • Nicholson B
        • Thor A
        • et al.
        A phase II trial of weekly doc etaxel and herceptin as first-or second-line treatment in HER2 overexpressing metastatic breast cancer.
        Proc Am Soc Clin Oncol. 2001; 20 (Abstract #1949).: 50b
        • Montemurro F
        • Choa G
        • Faggiuolo R
        • et al.
        Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study.
        Am J Clin Oncol. 2003; 26: 95-97
        • Burris III, HA
        Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer.
        Semin Oncol. 2001; 28: 38-44
        • Burstein HJ
        • Harris LN
        • Gelman R
        • et al.
        Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study.
        J Clin Oncol. 2003; 21: 46-53
        • Esteva FJ
        • Valero V
        • Booser D
        • et al.
        Phase II study of weekly docetaxel and trastuzumab for patient with HER-2 overexpressing metastatic breast cancer.
        J Clin Oncol. 2002; 20: 1800-1808
        • Levine PH
        • Steinhorn SC
        • Ries LG
        • et al.
        Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program.
        J Natl Cancer Inst. 1985; 74: 291-297
        • Haagensen CD
        The physiology of the breast as it concerns the clinician.
        Am J Obstet Gynecol. 1971; 109: 206-209
        • Jaiyesimi IA
        • Buzdar AU
        • Hortobagyi G
        Inflammatory breast cancer: a review.
        J Clin Oncol. 1992; 10: 1014-1024
        • Harries M
        • Smith I
        The development and clinical use of trastuzumab (Herceptin).
        Endocr Relat Cancer. 2002; 9: 75-85